Deutsche Bank’s GT Biopharma GTBP Stock Holding History

Deutsche Bank’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14	Closed	-$31K	–	4202
2022 Q1	$31K	Sell	14 -2	-13%	-$4.41K	﹤0.01%	3968
2021 Q4	$37K	Buy	16 +1	+7%	+$3.74K	﹤0.01%	4036
2021 Q3	$77K	Sell	15 -5	-25%	-$37.6K	﹤0.01%	3996
2021 Q2	$237K	Buy	+20	New	+$208K	﹤0.01%	3690

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank's GTBP Position: Q2 2022 in Review

Deutsche Bank sold out of GT Biopharma (GTBP) in Q2 2022, closing a stake of 14 shares — an estimated $31K sold.

Deutsche Bank first reported a position in GTBP in Q2 2021 and held it in 4 quarters. The position peaked at $237K in Q2 2021. 39 funds tracked by Wall St. Rank hold GTBP as of Q2 2022.

Deutsche Bank reported no remaining GT Biopharma position as of Q2 2022 after selling out during the quarter.
Deutsche Bank sold 14 GT Biopharma shares in Q2 2022, an estimated $31K.
Deutsche Bank first reported a position in GT Biopharma in Q2 2021 and held it in 4 quarters.
Deutsche Bank's GT Biopharma position peaked at $237K in Q2 2021.
39 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.